Smaller Deals, More Partnerships, and Continued Innovation in 2022.
Over the past few years, all things diagnostics have blossomed in life sciences markets, catalyzed by COVID. From swiftly commercializing massive innovation to invading the hearts and minds of everyday people as they strove to stay healthy and mobile, COVID pushed diagnostics to the forefront of investment and deal-making. COVID has resulted in a powerful deal market that filled portfolios and forces portfolio rationalization. And although COVID has started to wane, its effects have powered diagnostics and the pivotal place of the clinical lab for the long term.
As our team continues to help life sciences organizations navigate the current active deal market in the diagnostics space, we laid out key areas we are discussing with our clients, and those include:
Throughout this paper, we dive into what is happening in the diagnostics market, how the market has shifted, what we think will happen in the future and how KPMG can help. The diagnostics market has a novel and exciting future ahead. Contact one of our subject matter experts to learn more about how we can help you organization.
503B outsourcing facilities and pharma manufacturers
Why the growth of 503Bs may be an opportunity for traditional pharma
Liquid Biopsy – What’s real and what’s hype?
KPMG perspective on this innovative technology
Biopharma deal trends outlook for 2022
Deal strategies will focus on risk mitigation, accelerated development, or risk sharing (licensing, partnerships, R&D collaborations).